Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the ...

Greater baseline disease pruritus and quality of life impairment are associated with higher rates of super response to dupilumab in patients with AD.

A new injectable medicine is giving hope to people with asthma by helping them breathe better. The drug, called dupilumab ...

An anti-inflammation injectable drug called dupilumab can reduce mucus buildup and improve breathing among asthma patients, a ...

Dr S. Shahzad Mustafa looks ahead to ACAAI 2025, which will highlight advances in chronic urticaria treatment and ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...

Regeneron Pharmaceuticals and Sanofi SA have initiated a new clinical study titled ‘An Open-Label, Single-Arm Study to Assess Growth and Bone Mineral Density in Children ≥6 to ...

Determining a biologic's duration of use to treat pediatric atopic dermatitis has several factors, according to Lawrence ...

There are some 40 interleukins that play a wide variety of roles in inflammation and the body’s immune response, some of them hitting the accelerator and others tapping the brakes. When it comes to ...

Dupixent’s Q3 sales increased by 26.2%, breaking through the €4bn ceiling for the first time in a single quarter.

The "atopic march" describes the age-related progression of allergic diseases, presenting as the sequential onset of atopic ...